Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
ICML 2023
Is translocation 4;14 truly a marker of high-risk disease in #MultipleMyeloma?🤔🩸
Find out from @Dagostino_MD (@unito), who we had the pleasure of speaking with at #iwHRMM25:
👉 👈
#MMSM #Myeloma #HemOnc
Translocation 4;14 in multiple myeloma: is it truly a marker of high-risk disease?
Mattia D'Agostino, MD, University of Turin, Turin, Italy, discusses the variability in risk among patients with multip...
ow.ly
Post #ASH2025 Highlights: #MDS Webinar🩸 💻
Explore the most important #ASH25 data shaping the future of #myelodysplasticsyndromes (MDS)
Join an expert panel as they interpret key abstracts and discuss their real-world implications
👨⚕️ Chaired by: Prof. @Dr_AmerZeidan
🎙️…
Don't forget to listen to our recent episode on accelerated- and blast-phase MPNs with leading experts @Anand_88_Patel, @AdamMead_Oxford, @CKBrierley, & Juan Carlos Hernández-Boluda!🩸🎧
Click here to check it out:
🔗 https://ow.ly/C6vF50XuCAC
#MPNsm #BMTsm #Myelofibrosis…
In an interview from #SOHO2025, @drjoannarhodes1 of @RutgersCancer shares insights into the cost-effectiveness of continuous BTK inhibitor therapy in patients with CLL, outlining findings from a Medicare financial analysis.💰
Watch now:
🎥
#CLLsm #Leusm…
Cost-effectiveness of continuous BTK inhibitors in patients with CLL: a Medicare financial analysis
Joanna Rhodes, MD, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, shares insights into the cost-effectiven...
ow.ly
Have you had a chance to explore our exclusive content from #iwHRMM25? 🤔🎥
Watch all the presentations and expert-led discussions from this fantastic event to gain valuable insight into updates & advances in high-risk #myeloma.🩸
Click here: 👉 https://ow.ly/nKJB50Xqqe5
#MMSM…
ICML 2023
Is translocation 4;14 truly a marker of high-risk disease in #MultipleMyeloma?🤔🩸
Find out from @Dagostino_MD (@unito), who we had the pleasure of speaking with at #iwHRMM25:
👉 👈
#MMSM #Myeloma #HemOnc
Translocation 4;14 in multiple myeloma: is it truly a marker of high-risk disease?
Mattia D'Agostino, MD, University of Turin, Turin, Italy, discusses the variability in risk among patients with multip...
ow.ly
Post #ASH2025 Highlights: #MDS Webinar🩸 💻
Explore the most important #ASH25 data shaping the future of #myelodysplasticsyndromes (MDS)
Join an expert panel as they interpret key abstracts and discuss their real-world implications
👨⚕️ Chaired by: Prof. @Dr_AmerZeidan
🎙️…
Don't forget to listen to our recent episode on accelerated- and blast-phase MPNs with leading experts @Anand_88_Patel, @AdamMead_Oxford, @CKBrierley, & Juan Carlos Hernández-Boluda!🩸🎧
Click here to check it out:
🔗 https://ow.ly/C6vF50XuCAC
#MPNsm #BMTsm #Myelofibrosis…
In an interview from #SOHO2025, @drjoannarhodes1 of @RutgersCancer shares insights into the cost-effectiveness of continuous BTK inhibitor therapy in patients with CLL, outlining findings from a Medicare financial analysis.💰
Watch now:
🎥
#CLLsm #Leusm…
Cost-effectiveness of continuous BTK inhibitors in patients with CLL: a Medicare financial analysis
Joanna Rhodes, MD, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, shares insights into the cost-effectiven...
ow.ly
Have you had a chance to explore our exclusive content from #iwHRMM25? 🤔🎥
Watch all the presentations and expert-led discussions from this fantastic event to gain valuable insight into updates & advances in high-risk #myeloma.🩸
Click here: 👉 https://ow.ly/nKJB50Xqqe5
#MMSM…
